INVO Fertility, Inc. (IVF) - Dilution Analysis

8-K filing: Stock split 1-for-5 | Outstanding: 15,130,282 → 3,026,056

8-K filing: INVO Fertility, Inc. entered into an inducement letter agreement with an institutional investor to exercise existing warrants for cash at a reduced price of $1.59 per share, resulting in the issuance of 4,733,728 shares of common stock and the issuance of new unregistered warrants to purchase up to 9,467,456 shares of common stock at an exercise price of $1.59 per share. ($7.53M proceeds)

S-1 filing: INVO Fertility, Inc. is offering up to 7,372,122 shares of common stock, including shares issuable upon conversion of preferred stock and exercise of warrants held by selling stockholders.

10-Q filing | 15.1M shares outstanding

8-K filing: On October 16, 2025, an institutional investor exercised its Additional Investment Right to acquire 500 shares of Series C-2 Convertible Preferred Stock for $500,000 in cash. ($0.5M proceeds)

8-K filing: INVO Fertility, Inc. sold 200 shares of Series C-2 Convertible Preferred Stock to an existing institutional investor for $200,000 on October 6, 2025, resulting in an adjustment to the conversion price. ($0.2M proceeds)

8-K filing: INVO Fertility, Inc. finalized a settlement agreement with Dr. Elizabeth Pritts and an institutional investor exercised its Additional Investment Right to acquire 400 shares of C-2 Preferred Stock for $400,000. ($0.4M proceeds)

8-K filing: Five Narrow Lane LP exchanged a Second Amended and Restated Senior Secured Convertible Debenture for shares of Series C-2 Convertible Preferred Stock and the company issued 467 additional shares of Series C-2 Preferred Stock to FNL.

8-K filing: INVO Fertility, Inc. sold 200 shares of Series C-2 Convertible Preferred Stock to an existing institutional investor for $200,000 in cash on September 8, 2025, resulting in a conversion price adjustment to $0.7362 per share. ($0.2M proceeds)

8-K filing: INVO Fertility, Inc. and Five Narrow Lane LP entered into an Amendment and Exchange Agreement, reducing the Second Amended and Restated Debenture by $1,300,000 in exchange for 325 shares of the Company's Series C-2 Preferred Stock. ($1.3M proceeds)

10-Q filing | 4.4M shares outstanding

8-K filing: INVO Fertility, Inc. completed a 1-for-3 reverse stock split on July 21, 2025, and an institutional investor exercised its right to acquire 200 shares of Series C-2 Convertible Preferred Stock for $200,000 on July 17, 2025. ($0.2M proceeds)

8-K filing: NAYA Therapeutics Inc. entered into an agreement to issue 1,800 shares of C-2 Preferred in exchange for debt, issued 630 shares of new C-2 Preferred, and sold 500 shares of C-2 Preferred for $500,000 in cash, while also amending the rights of the C-2 Preferred stock. ($0.5M proceeds)

8-K filing: The company entered into multiple agreements, including the NTI Exchange Agreement for exchanging shares, amendments to preferred stock designations and debentures, and agreements relating to secured convertible promissory notes and security interests, and also redeemed all outstanding Series C-1 Preferred Stock at a redemption price of 113.855837742504 shares of Class A Common Stock of NTI for each share of C-1 Preferred being redeemed.

10-Q filing | 2.1M shares outstanding

8-K filing: INVO Fertility, Inc. entered into an inducement letter agreement with an institutional investor to purchase up to 465,840 shares of the Company's common stock at an exercise price of $1.61 per share, with gross proceeds to the Company of approximately $750,000. ($0.75M proceeds)

10-K filing | 1.1M shares outstanding

8-K filing: NAYA Biosciences, Inc. consummated a public offering of 13,615,171 units at $0.70 per unit, consisting of common stock or pre-funded warrants and warrants, raising gross proceeds of approximately $9.5 million. ($9.53M proceeds)

S-1/A filing: NAYA Biosciences, Inc. is offering up to 14,942,529 units, each consisting of one share of common stock or one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, with an assumed public offering price of $0.87 per Unit.

S-1/A filing: NAYA Biosciences, Inc. is offering up to $13,000,000 of units, each consisting of one share of common stock and one warrant to purchase one share of common stock at an assumed public offering price of $0.87 per Unit.

S-1 filing: NAYA Biosciences, Inc. is offering up to $10,000,000 of units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and pre-funded warrants to purchase common stock in lieu of common stock for certain purchasers.

S-3/A filing: This S-3/A filing registers NAYA Biosciences, Inc. securities, including common stock, preferred stock, debt securities, warrants, and units, for a total offering amount not to exceed $100,000,000, to be offered and sold from time to time.

10-Q filing | 4.9M shares outstanding

8-K filing: INVO consummated a merger with NAYA, resulting in the issuance of common stock and preferred stock, and the company plans to effectuate a reverse stock split at a ratio ranging from any whole number between 1-for-2 and 1-for-20 to regain compliance with Nasdaq listing rules.

8-K filing: INVO Bioscience, Inc. entered into a fourth amendment to the merger agreement with NAYA Biosciences, Inc., extending the end date to October 14, 2024, and agreeing to a purchase of 27,500 shares of Series A Preferred Stock by NAYA for $137,500. ($0.14M proceeds)

10-Q filing | 3.6M shares outstanding

8-K filing: INVO Bioscience, Inc. extended the maturity date of its convertible notes to December 31, 2024, lowered the conversion price and warrant exercise price to $1.20, provided early repayment rights, and increased the number of shares of common stock available under the warrants to 118,754.

S-3 filing: This S-3 filing discusses the completion of a merger, conditions related to the merger, termination rights, and a private offering of common stock at a target price of $5.00 per share to ensure sufficient cash for one year of operations.

10-Q filing | 3.8M shares outstanding

8-K filing: INVO Bioscience, Inc. entered into a third amendment to the merger agreement with NAYA Biosciences, Inc., extending the end date to June 30, 2024, and modifying the definition of an 'Interim PIPE'. The company also entered into an amendment to the Securities Purchase Agreement for NAYA's purchases of the remaining 838,800 shares of the Company's Series A Preferred Stock at $5.00 per share. ($4.19M proceeds)

8-K filing: INVO Bioscience, Inc. amended its warrant agency agreement with Transfer Online, Inc. to allow for the adjustment of the warrants' exercise price, subsequently reducing it from $2.85 to $1.20 per share.

10-K filing | 2.7M shares outstanding

8-K filing: INVO Bioscience, Inc. entered into a purchase agreement with FirstFire Global Opportunities Fund, LLC, issuing a convertible promissory note, warrants to purchase common stock, and commitment shares for a total purchase price of $250,000, with Carter, Terry, & Company, Inc. acting as placement agent. ($0.25M proceeds)

8-K filing: INVO Bioscience, Inc. entered into a purchase agreement with Triton Funds LP to sell up to 1,000,000 shares of common stock at $0.85 per share, providing gross proceeds of up to $850,000, and also sold private placement warrants to Triton to purchase up to 1,000,000 shares of common stock at an exercise price of $2.00 per share. ($0.85M proceeds)

8-K filing: INVO Bioscience, Inc. entered into a securities purchase agreement with NAYA Bioscience, Inc. on December 29, 2023, for NAYA's purchase of 1,000,000 shares of the Company's Series A Preferred Stock at $5.00 per share, but NAYA failed to fund the second tranche by January 31, 2024. ($5.0M proceeds)

8-K filing: INVO Bioscience, Inc. entered into a securities purchase agreement with NAYA Biosciences, Inc. for the purchase of 1,000,000 shares of the Company's Series A Preferred Stock at $5.00 per share, with the first tranche of 100,000 shares closing on January 4, 2024, for gross proceeds of $500,000. ($0.5M proceeds)

8-K filing: INVO Bioscience entered into a second amendment to the merger agreement with NAYA Biosciences, extending the end date to April 30, 2024, and modifying the closing condition for an interim private offering and also entered into a securities purchase agreement with NAYA for the purchase of 400,000 shares of Series A Preferred Stock at $5.00 per share. ($2.0M proceeds)

8-K filing: INVO Bioscience, Inc. amended a Common Stock Purchase Warrant with an institutional investor to reduce the exercise price to $2.85 per share, after a 1-for-20 reverse stock split in July 2023.

8-K filing: INVO Bioscience, Inc. announced that it had received a notice from Nasdaq informing the Company that it has regained compliance with Nasdaq's Listing Rule 5550(b)(1). On November 20, 2023, the Company entered into a share exchange agreement with Cytovia Therapeutics Holdings, Inc. for Cytovia's acquisition of 1,200,000 shares of the Company's newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA Biosciences Inc. held by Cytovia valued at $6,000,000 and closed on the exchange of shares. ($6.0M proceeds)

8-K filing: Cytovia acquired 1,200,000 shares of the company's newly designated Series B Preferred Stock in exchange for 163,637 shares of NAYA common stock valued at $6,000,000. ($6.0M proceeds)

10-Q filing | 2.5M shares outstanding

10-Q filing | 2.4M shares outstanding

8-K filing: INVO Bioscience, Inc. completed a public offering of 1,580,000 units at $2.85 per unit, with each unit consisting of one share of common stock and two warrants, raising gross proceeds of approximately $4.5 million. ($4.5M proceeds)

S-1/A filing: The company is engaged in a public offering of common stock, common stock purchase warrants, and pre-funded warrants.

8-K filing: Stock split 1-for-20 | Outstanding: 16,537,580 → 6,250,000

S-1/A filing: This S-1/A filing from 2023-07-24 discusses the issuance of common stock purchase warrants and common stock to consultants for services rendered.

8-K filing: INVO Bioscience, Inc. entered into a Standard Merchant Cash Advance Agreement with Cedar Advance LLC for $375,000 and an amended letter agreement with JAG Multi Investments LLC rescinding a warrant issuance.

S-1 filing: S-1 filing regarding the issuance of Placement Agent Warrants to the Placement Agent, covering a number of shares of common stock equal to seven percent (7.0%) of the total number of securities sold in the offering.

S-1/A filing: This prospectus relates to the offer and resale by the Selling Stockholders of up to 6,241,493 shares of restricted Common Stock and Common Stock issuable upon the exercise of the Warrants and conversion of the Debentures.

S-1 filing: This prospectus relates to the offer and resale by the Selling Stockholders of up to 6,241,493 shares of restricted Common Stock and Common Stock issuable upon the exercise of the Warrants and conversion of the Debentures.

10-Q filing | 14.0M shares outstanding

10-K filing | 14.0M shares outstanding

8-K filing: INVO Bioscience, Inc. closed a registered direct offering and concurrent private placement on March 27, 2023, issuing 1,380,000 shares of common stock, pre-funded warrants to purchase up to 2,300,000 shares, and private placement warrants exercisable for up to 5,520,000 shares, raising gross proceeds of approximately $3 million before deducting fees. ($3.0M proceeds)

8-K filing: The Company entered into definitive securities purchase agreements with accredited investors for the purchase of unsecured convertible notes and 5-year warrants to purchase shares of the Company's common stock in a private placement.

8-K filing: INVO Bioscience Inc. entered into purchase agreements through its subsidiary Wood Violet Fertility LLC to acquire Wisconsin Fertility Institute for $10 million, payable in installments with an option for the sellers to take INVO common stock in lieu of cash payments.

8-K filing: INVO Bioscience, Inc. completed a private placement with Firstfire Global Opportunities Fund, LLC, involving a convertible debenture, a warrant, and commitment shares, with Carter, Terry, & Company, Inc. acting as placement agent.

8-K filing: INVO Bioscience, Inc. entered into a securities purchase agreement with Peak One Opportunity Fund, LP for a convertible debenture, warrant, and commitment shares, and an Equity Purchase Agreement to sell shares of common stock.

8-K filing: The Company entered into definitive securities purchase agreements with accredited investors for the purchase of convertible notes and warrants to purchase the Company's common stock.

10-Q filing | 12.2M shares outstanding

10-Q filing | 12.1M shares outstanding

10-Q filing | 12.1M shares outstanding

10-K filing | 12.1M shares outstanding

8-K filing: INVO Bioscience, Inc. sold 94,623 shares of common stock to Paradigm Opportunities Fund, LP on January 31, 2022, for gross proceeds of $315,000, with plans to use the funds for working capital and general corporate purposes. ($0.32M proceeds)

8-K filing: On December 31, 2021, the company entered into a Second Amendment to Stock Purchase Agreement with Paradigm Opportunities Fund, LP, to sell 600,703 shares of common stock at $3.329 per share for an aggregate purchase price of $1,999,740.29, with the closing date extended to January 31, 2022. ($2.0M proceeds)

8-K filing: The company entered into an amendment to a stock purchase agreement with Paradigm Opportunities Fund, LP to sell 600,703 shares of common stock at $3.329 per share for an aggregate purchase price of $1,999,740.29, with the closing date extended to December 31, 2021. ($2.0M proceeds)

10-Q filing | 11.7M shares outstanding

8-K filing: The Company entered into a securities purchase agreement to issue and sell 1,240,737 shares of its common stock in a registered direct offering for aggregate gross proceeds of $4,044,802.62. ($4.44M proceeds)

8-K filing: On October 1, 2021, the company entered into a Stock Purchase Agreement with Paradigm Opportunities Fund, LP, to issue 600,703 shares of common stock at $3.329 per share, for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. ($2.0M proceeds)

10-Q filing | 10.4M shares outstanding

8-K filing: INVO Centers, LLC, a wholly-owned subsidiary of INVO Bioscience, entered into a joint venture agreement with Bloom Fertility, LLC to form Bloom INVO LLC, which will establish a fertility center offering INVO Technologies.

10-Q filing | 9.9M shares outstanding

S-3 filing: The company may offer and sell up to $35,000,000 in the aggregate of common stock, preferred stock, debt securities, warrants and units from time to time in one or more offerings.

10-K filing | 10.4M shares outstanding

8-K filing: INVO Bioscience subsidiary, INVO Centers, LLC, entered into a JV LLC Agreement with HRCFG, LLC to form a joint venture named HRCFG INVO LLC for commercializing INVOcell technologies, with INVO Centers providing the technology and funding, and HRCFG providing clinical expertise. INVO Bioscience will issue 25,000 shares of common stock to HRCFG upon the opening of the BHAM Clinic, and an additional 25,000 shares for each additional INVOcell-based clinic opened by the JV Company.

8-K filing: INVO Bioscience, Inc. completed a public offering of 4,153,750 shares of common stock, including the exercise of an underwriter's option, resulting in net proceeds of approximately $11.62 million. ($11.65M proceeds)

8-K filing: INVO Bioscience, Inc. closed a public offering of 3,625,000 shares of common stock at $3.20 per share on November 17, 2020, resulting in net proceeds of approximately $10.1 million. ($10.1M proceeds)

10-Q filing | 4.9M shares outstanding

8-K filing: INVO Bioscience, Inc. entered into an underwriting agreement for a public offering of 3,625,000 shares of common stock at $3.20 per share, with an option for the underwriters to purchase an additional 543,750 shares. ($10.1M proceeds)

S-1/A filing: The company is offering 2,035,000 shares of common stock, with an underwriter option for an additional 305,250 shares to cover over-allotments.

8-K filing: Stock split 5-for-8 reverse | Outstanding: 7,892,707 → 4,953,910

S-1/A filing: INVO Bioscience, Inc. is offering up to 2,750,000 shares of common stock, with an option for underwriters to purchase up to an additional 412,500 shares, pursuant to the Underwriting Agreement.

S-1/A filing: Registration of 2,750,000 shares of common stock and an option to purchase up to an additional 412,500 shares of common stock.

S-1/A filing: The filing is for an offering of 2,750,000 shares of common stock, with an option for the underwriters to purchase an additional 412,500 shares to cover over-allotments.

S-1/A filing: The filing is an S-1/A form indicating an offering of 2,750,000 shares of common stock, with an option for underwriters to purchase an additional 412,500 shares. The last reported sale price was $4.04 per share.

S-1 filing: The company is offering common stock. The last reported sale price of the common stock was $4.00 per share on September 18, 2020.

10-Q filing | 7.9M shares outstanding

S-1 filing: This prospectus covers the resale of 970,789 shares of our common stock issuable upon conversion of $3,494,840 of certain 10% convertible promissory notes; 485,783 shares of our Common Stock issuable upon exercise of units issued under outstanding unit purchase options; 485,783 shares of our Common Stock issuable upon the exercise of warrants issuable upon exercise of the units issued under outstanding unit purchase options; and 10,800 shares of our Common Stock issuable upon the exercise of warrants issuable to the placement agent and selling agent upon exercise of warrants.

8-K filing: The Company held its final closing on June 30, 2020 and entered into definitive securities purchase agreements with accredited investors for the purchase of secured convertible notes in the aggregate original principal amount of $401,200 and Unit Purchase Options to purchase 55,797 units at an exercise price of $5.00 per Unit.

8-K filing: The Company entered into definitive securities purchase agreements with accredited investors for the purchase of secured convertible notes and Unit Purchase Options, receiving gross cash proceeds of $988,640 million at the Second Closing and approximately $2.65 million in net proceeds from both the Initial Closing and the Second Closing.

8-K filing: Stock split 1-for-20 | Outstanding: 157,375,918 → 7,888,717

10-Q filing | 157.4M shares outstanding

10-K filing | 155.4M shares outstanding